Skip to primary navigation
Skip to main content
Skip to primary navigation
Skip to main content
Toggle Search
Search
Choose which site to search.
Current site
All of UAMS
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller
Cancer Institute
UAMS Health
Jobs
Giving
Toggle Search
Toggle Primary Nav
About
From the Director
Our History
Leadership
Board of Advisors
About Little Rock
Maps & Directions
Cancer Institute Magazine
News
College of Medicine
Patient Care
Clinical Trials
Research
Research Programs
Membership
Clinical Research
Funding Opportunities
Shared Resources
Research Space Policy
Outreach
Training and Education
Get Involved
Donate
Fundraising Events
Volunteer Services & Auxiliary
The Envoys
Contact
University of Arkansas for Medical Sciences
Winthrop P. Rockefeller Cancer Institute
All Clinical Trials
Trials: All Clinical Trials
You are here:
Find a Clinical Trial
All Clinical Trials
A Prospective Observational Study of Patients with Monoclonal Gammopathy (MGUS) and Asymptomatic Mulitple Myeloma
June 10, 2026
Assessing Dynamic Changes in the Plasma Proteome to Identify Clinically Relevant Early Detection and Treatment Response Biomarkers for High Grade Serous Ovarian Cancer: A CPTAC Pilot Project.
June 10, 2026
Detection of Doxorubicin Cardiotoxicity Using Peripheral Blood Transcriptome
June 10, 2026
Evaluation of a flow cytometry assay measuring BCMA CAR-T cells and T cell characterization in treated patients
June 10, 2026
Gut Microbiome in Acute Leukemia and Allogeneic Stem Cell Transplant Patients
June 24, 2026
Gut Microbiome in Acute Leukemia and Allogeneic Stem Cell Transplant Patients
June 29, 2026
NCT00969111 – GU010-18 Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
June 10, 2026
NCT01530373 – A Phase II Randomized Study of Solifenacin Compared to Clonidine for Reducing Hot Flashes among Breast Cancer Patients Receiving Adjuvant Hormonal Therapy
June 10, 2026
NCT01776905 – (IRB#133965) In vivo real-time detection of circulating melanoma cells
June 10, 2026
NCT02305654 – EA8134 InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
June 10, 2026
NCT02598349 – PAN009-18 A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
June 10, 2026
NCT03678025 – S1802 “Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
June 10, 2026
NCT03801876 – NRG-GI006 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
June 10, 2026
NCT03801876 – NRG-GI006 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
June 10, 2026
NCT03851445 – LUNGMAP – A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
June 10, 2026
NCT04239573 – EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
June 10, 2026
NCT04251052 – A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
June 10, 2026
NCT04333537 – NRG HN006 Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
June 10, 2026
NCT04400591 – Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release
June 10, 2026
NCT04634552 – A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
June 10, 2026
NCT04637763 – A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
June 24, 2026
NCT04637763 – A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
June 29, 2026
NCT04671667 – EA3191 A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
June 10, 2026
NCT04771078 – Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release
June 10, 2026
NCT05061550 – A Phase II Open-label, Multicenter, Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
June 24, 2026
NCT05061550 – A Phase II Open-label, Multicenter, Randomized Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
June 10, 2026
NCT05096663 – S1900G, “A Randomized Phase II Study of INC280 (capmatinib) plusOsimertinib with or without Ramucirumab in Participants with EGFR-Mutant, METAmplifiedStage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)”
June 10, 2026
NCT05136196 – S2101 Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) – A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study
June 10, 2026
NCT05174169 – NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)
June 10, 2026
NCT05256225 – NRG-GY026: a Phase ii/iii Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (Phesgo) in Her2 positive, Stage i-iv Endometrial Serous Carcinoma or Carcinosarcoma
June 10, 2026
NCT05327686 – NRG-GU012 – Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
June 10, 2026
NCT05346835 – Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
June 10, 2026
NCT05548296 – A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
June 10, 2026
NCT05554406 – MM1YA-S01, “A Randomized Phase II Study Comparing Cytarabine + Daunorubicin(7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin +Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome+ Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk(Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; AMyeloMATCH Clinical Trial”
June 24, 2026
NCT05561387 – S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance
June 24, 2026
NCT05564390 – MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
June 10, 2026
NCT05633615 – S2114: A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
June 10, 2026
NCT05675449 – A Phase 1B, Open-label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma
June 10, 2026
NCT05879926 – NRG-BR009 A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
June 10, 2026
NCT05929768 – S2212, Shorter Anthracycline-Free Chemo Immunotherapy Adapted Topathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
June 10, 2026
NCT05932680 – Phase 2, Single-Arm, Non-Inferiority Study of Limited-Duration Teclistamab for Relapsed Refractory Multiple Myeloma
June 10, 2026
NCT05946213 – NRG-GU013, “The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer”
June 10, 2026
NCT05952934 – A Phase II Clinical Trial of Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
June 10, 2026
NCT06031688 – S1900K A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
June 10, 2026
NCT06044025 – A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients with Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
June 10, 2026
NCT06072781 – A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
June 10, 2026
NCT06116682 – S1900J A Phase II Study of Amivantamab SC (Subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)
June 10, 2026
NCT06157151 – A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer
June 10, 2026
NCT06203600 – S2303, Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel +Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
June 10, 2026
NCT06246916 – A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma
June 10, 2026
NCT06253130 – A First-In-Human, Phase 1/2, Open-Label, Multi-Center, Dose-Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy and in Combination in Participants with Advanced Solid Tumors
June 10, 2026
NCT06312137 – A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
June 10, 2026
NCT06337318 – S2308 Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
June 24, 2026
NCT06457503 – TRANSPARENT: Single-Arm Study of Toripalimab in Combination with Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants
June 10, 2026
NCT06470243 – S2312, “A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-resistant Prostate Cancer (MCrPC), Stratified by Aggressive Variant Signature”
June 10, 2026
NCT06500455 – NRG-BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases
June 10, 2026
NCT06500481 – NRG-BN014: A Phase III Randomized Clinical Trial of Proton Craniospinal Irradiation versus Involved-Field Radiotherapy for Patients with Breast Cancer or Non-Small Cell Lung Cancer Leptomeningeal Metastasis (RADIATE-LM)
June 10, 2026
NCT06515613 – A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors
June 10, 2026
NCT06567743 – A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
June 10, 2026
NCT06568939 – A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
June 10, 2026
NCT06580314 – NRG GY036 A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
June 10, 2026
NCT06586957 – A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer
June 10, 2026
NCT06589804 – A092205 Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease
June 10, 2026
NCT06852222 – A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of BLEXIMENIB, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy
June 24, 2026
REG001-09 Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy
June 10, 2026
Sentinel Lymph Node Working Group Database Acquisition Project
June 29, 2026
Validation of OvaPrintTM cell-free DNA Methylation Liquid Biopsy in women with Pelvic Masses
June 29, 2026
